The answer so far
The pancreas helps digest food and regulates blood sugar. Pancreatitis has several possible causes, so pain cannot identify the cause by itself.
Severe, persistent abdominal pain needs urgent medical attention, especially if it spreads to the back or occurs with vomiting. Acute pancreatitis means inflammation of the pancreas. It has been reported in people taking these medicines, and regulators warn about a potential risk. Trial reviews disagree about the size—or presence—of any increased risk.134
On this page
Can GLP-1 medicines cause pancreatitis? Choose a step to explore this subject in more detail.
Urgent first step: severe, persistent pain
The urgent symptom is severe, persistent abdominal pain, especially pain that spreads to the back or comes with nausea or vomiting. In January 2026 the UK MHRA strengthened warnings for GLP-1 and dual GLP-1/GIP medicines, including semaglutide and tirzepatide, after reports of severe acute pancreatitis, including rare necrotising and fatal cases. Reports are important safety signals, but they cannot prove that a medicine caused each event or provide a reliable rate among everyone taking it. A clinician assesses suspected pancreatitis and the medicine. The MHRA tells healthcare professionals to stop the medicine if pancreatitis is suspected. The MHRA also advises that these medicines should not be restarted if pancreatitis is confirmed, and should be used with caution in people with a history of pancreatitis. Tell the prescriber about any prior pancreatitis when discussing treatment.1
Why do research reviews differ?
A 2024 review of randomized semaglutide trials did not find a statistically significant increase in acute pancreatitis compared with placebo. A 2025 review combining trials of several related medicines reported an increased risk in its overall analysis, while some subgroup estimates were not statistically significant. The reviews included different drugs and studies. Pancreatitis events are uncommon, so estimates can be imprecise; a non-significant result does not prove zero risk, and a pooled result does not establish the risk of every product or person.34
What symptoms need urgent attention?
The MHRA advises urgent medical attention for severe, persistent abdominal pain that may spread to the back and may be accompanied by nausea or vomiting. Pancreatitis can be serious and needs clinical assessment. Common nausea or mild digestive symptoms do not by themselves diagnose pancreatitis, but severe or persistent pain should not be dismissed as an expected side effect.12
Could it be the gallbladder instead?
Gallstones and other conditions can cause abdominal symptoms, and gallstones are also a cause of pancreatitis. Only an appropriate clinical assessment can distinguish possible causes. See weight-loss medicines and gallbladder problems for that separate evidence. If symptoms are severe or persistent, seek urgent care rather than trying to diagnose them from this guide.2
Putting the evidence in context
A product label, a spontaneous safety report and a randomized trial answer different questions. Benefits, underlying conditions, prior pancreatitis, other medicines and the exact product all matter in an individual discussion. This guide does not estimate a personal risk or recommend starting or stopping treatment on the basis of an article. For broader benefits and harms, see semaglutide and tirzepatide.1
Further reading
Trusted external resources selected to help explain this page. They open in a new tab.
- UK safety update on acute pancreatitis ↗January 2026; reports do not establish individual causation or incidence.
- Pancreatitis symptoms and causes ↗Explains symptoms and causes; clinical evaluation is needed.
- Semaglutide and pancreatitis: 2024 review ↗Semaglutide-specific trials; non-significant result does not prove zero risk.
- Related medicines and pancreatitis: 2025 review ↗Pooled different medicines and studies; subgroup results were less precise.
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitisUK Medicines and Healthcare products Regulatory Agency · UK regulator safety update, January 2026
- Symptoms & Causes of PancreatitisUS National Institute of Diabetes and Digestive and Kidney Diseases · US public-health clinical information
- Acute pancreatitis due to different semaglutide regimens: An updated meta-analysisEndocrinología, Diabetes y Nutrición / PubMed · Systematic review and meta-analysis of randomized trials, 2024
- Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled TrialsEndocrinology, Diabetes & Metabolism / PubMed · Systematic review and meta-analysis of randomized trials, 2025